The founder sold the controlling stake at a 30% premium. Will Shaanxi Kanghui Pharmaceutical still sell medications in the future? | Quick read of the announcement

① Kanghui Holdings transferred 22% of its shares in Shaanxi Kanghui Pharmaceutical at 24.70 yuan/share, reflecting a premium of 31.24% compared to the price before the suspension. ② The business scope of the transferee, Yuehe Zhichuang, does not include any mention related to pharmaceuticals.

cls.cnMar 20 11:04 ET

After two trading limit increases, Shaanxi Kanghui Pharmaceutical officially announced plans for a change in control, refuting rumors of a shell acquisition by Hengchang Pharmaceutical | Quick announcement summary.

① Due to the controlling shareholder planning a share transfer, Shaanxi Kanghui Pharmaceutical Stocks have been suspended from trading since the 19th. ② Shaanxi Kanghui Pharmaceutical stated that, aside from a small collaboration with Hengchang Pharmaceutical on a Business level, there is no related cooperation in terms of backdoor listing.

cls.cnMar 18 11:53 ET

A large number of consultations! The benefits of childcare subsidies continue to be released, and Assisted Reproduction companies are looking forward to a "combination punch."

① Recently, policies favorable for child-rearing have emerged from both central and local governments, with some regions even offering substantial monetary incentives to encourage childbirth. ② Industry experts pointed out to reporters at Caijing that the introduction of child-rearing subsidy policies can, to some extent, reduce the burden and concerns for young couples regarding childbirth. ③ Insiders from Assisted Reproduction companies have expressed that measures such as promoting cultural awareness of male responsibility in child-rearing are also highly anticipated in the industry.

cls.cnMar 17 01:44 ET

National People's Congress representative, Zhao Jing of Shandong Buchang Pharmaceuticals: "The 'AI+' is reaching a critical point of explosion. It is recommended to utilize AI to empower the inheritance and innovation of Traditional Chinese Medicine | Two

① Zhao Jing, a representative of the National People's Congress and Vice Director of Shandong Buchang Pharmaceuticals, brought the proposal "Utilizing AI to Empower the Inheritance and Innovation of Traditional Chinese Medicine and Build a New Pattern of Development for Traditional Chinese Medicine with 'Asia Vets + Technology'" to this year's Two Sessions, aiming to promote the intelligent upgrade of the Traditional Chinese Medicine industry through AI technology. ② Zhao Jing stated that the development of large models like DeepSeek has indeed pushed the integration of Traditional Chinese Medicine and AI to a critical point of explosion.

cls.cnMar 6 20:48 ET

Guizhou Xinbang Pharmaceutical's subsidiary is embroiled in a bribery scandal; what is the impact?

① Company personnel stated that this matter currently has no impact on the company's operation, and the subsidiary mainly engages in in-hospital pharmaceutical wholesale. Even if penalized later, it will not involve qualification issues. ② Industry experts believe that the short-term impact is significant, while the long-term impact is minimal. In the short term, the principal company may be listed as untrustworthy due to the crime of unit bribery, which would exclude it from the bidding procurement of local hospitals in Guizhou for a period. However, in the long term, since it is not a quality issue, there are opportunities for repair.

cls.cnMar 4 09:08 ET

Former TJ DaRenTang Chairman Zhang Mingrui has taken over as General Manager of Hainan Huluwa Pharmaceutical Group, responsible for the company's overall Operation work | Quick read announcement

① Former TJ DaRenTang Chairman Zhang Mingrui has been appointed General Manager of Hainan Huluwa Pharmaceutical Group. Company sources indicate, "Chairman Liu Jingping will primarily focus on the work related to the Board of Directors in the future, while General Manager Zhang Mingrui will be responsible for the company's overall Operation." ② Company sources also noted that this year marks the year of Hainan's customs closure, and the company is facing significant opportunities for strategic development. The company's invitation for Mr. Zhang is also strategical.

cls.cnMar 4 06:15 ET